Ovarian stimulation protocols for poor ovarian responders: a network meta-analysis of randomized controlled trials

[1]  Dr Ying Qin.  Effects of using letrozole in combination with the GnRH antagonist protocol for patients with poor ovarian response: a meta-analysis. , 2021, Journal of gynecology obstetrics and human reproduction.

[2]  Yanping Li,et al.  Efficacy of the delayed start antagonist protocol for controlled ovarian stimulation in Bologna poor ovarian responders: a systematic review and meta-analysis , 2020, Archives of Gynecology and Obstetrics.

[3]  P. Bakas,et al.  The Conundrum of Poor Ovarian Response: From Diagnosis to Treatment , 2020, Diagnostics.

[4]  S. R. Salian,et al.  Reduced ovarian response to controlled ovarian stimulation is associated with increased oxidative stress in the follicular environment. , 2020, Reproductive biology.

[5]  Xiaoping Liu,et al.  Mild stimulation protocol vs conventional controlled ovarian stimulation protocol in poor ovarian response patients: a prospective randomized controlled trial , 2020, Archives of Gynecology and Obstetrics.

[6]  P. Humaidan,et al.  Novel Physiology and Definition of Poor Ovarian Response; Clinical Recommendations , 2020, International journal of molecular sciences.

[7]  S. You,et al.  Acupuncture for in vitro fertilization in women with poor ovarian response: a systematic review , 2020, Integrative medicine research.

[8]  P. Leung,et al.  Adjuvant treatment strategies in ovarian stimulation for poor responders undergoing IVF: a systematic review and network meta-analysis. , 2020, Human reproduction update.

[9]  F. Ghaffari,et al.  Randomized controlled trial of gonadotropin‐releasing hormone agonist microdose flare‐up versus flare‐up among poor responders undergoing intracytoplasmic sperm injection , 2020, International journal of gynaecology and obstetrics: the official organ of the International Federation of Gynaecology and Obstetrics.

[10]  M. Cozzolino,et al.  "Delayed start" gonadotropin-releasing hormone antagonist protocol in Bologna poor-responders: A systematic review and meta-analysis of randomized controlled trials. , 2019, European journal of obstetrics, gynecology, and reproductive biology.

[11]  Xuefeng Lu,et al.  Progestin vs. Gonadotropin-Releasing Hormone Antagonist for the Prevention of Premature Luteinizing Hormone Surges in Poor Responders Undergoing in vitro Fertilization Treatment: A Randomized Controlled Trial , 2019, Front. Endocrinol..

[12]  A. Qin,et al.  Progestin-primed ovarian stimulation is a feasible method for poor ovarian responders undergoing in IVF/ICSI compared to a GnRH antagonist protocol: A retrospective study. , 2019, Journal of gynecology obstetrics and human reproduction.

[13]  M. Ashrafi,et al.  Does the “delayed start” protocol with gonadotropin-releasing hormone antagonist improve the pregnancy outcome in Bologna poor responders? a randomized clinical trial , 2018, Reproductive Biology and Endocrinology.

[14]  B. Jahromi,et al.  Delayed Start Protocol with Gonadotropin-releasing Hormone Antagonist in Poor Responders Undergoing In Vitro Fertilization: A Randomized, Double-blinded, Clinical Trial. , 2018, Oman medical journal.

[15]  R. Davar,et al.  Pregnancy outcome in delayed start antagonist versus microdose flare GnRH agonist protocol in poor responders undergoing IVF/ICSI: An RCT , 2018, International journal of reproductive biomedicine.

[16]  Dimitris Mavridis,et al.  Living network meta-analysis compared with pairwise meta-analysis in comparative effectiveness research: empirical study , 2018, British Medical Journal.

[17]  K. Yang,et al.  Efficacy of luteal estrogen administration and an early follicular Gonadotropin-releasing hormone antagonist priming protocol in poor responders undergoing in vitro fertilization , 2017, Obstetrics & gynecology science.

[18]  I. Koenig,et al.  Ovarian response to 150 µg corifollitropin alfa in a GnRH-antagonist multiple-dose protocol: a prospective cohort study. , 2017, Reproductive biomedicine online.

[19]  A. Aflatoonian,et al.  Pregnancy outcome of “delayed start” GnRH antagonist protocol versus GnRH antagonist protocol in poor responders: A clinical trial study , 2017, International journal of reproductive biomedicine.

[20]  H. Kraemer.  Multiple-Treatments Meta-Analysis: Are the Conclusions Supported by the Data? , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  M. Ebrahimi,et al.  Letrozole+ GnRH antagonist stimulation protocol in poor ovarian responders undergoing intracytoplasmic sperm injection cycles: An RCT , 2017, International journal of reproductive biomedicine.

[22]  F. Ciardo,et al.  Short gonadotropin-releasing hormone agonist versus flexible antagonist versus clomiphene citrate regimens in poor responders undergoing in vitro fertilization: a randomized controlled trial. , 2016, European review for medical and pharmacological sciences.

[23]  A. Maged,et al.  Delayed Start Versus Conventional GnRH Antagonist Protocol in Poor Responders Pretreated With Estradiol in Luteal Phase , 2015, Reproductive Sciences.

[24]  M. Bakacak,et al.  The comparision of effect of microdose GnRH-a flare-up, GnRH antagonist/aromatase inhibitor letrozole and GnRH antagonist/clomiphene citrate protocols on IVF outcomes in poor responder patients , 2014, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[25]  M. Cedars,et al.  A novel "delayed start" protocol with gonadotropin-releasing hormone antagonist improves outcomes in poor responders. , 2014, Fertility and sterility.

[26]  H. Fatemi,et al.  High ovarian response does not jeopardize ongoing pregnancy rates and increases cumulative pregnancy rates in a GnRH-antagonist protocol. , 2013, Human reproduction.

[27]  Iman Abdel Mohsen,et al.  Minimal stimulation protocol using letrozole versus microdose flare up GnRH agonist protocol in women with poor ovarian response undergoing ICSI , 2013, Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology.

[28]  E. Anckaert,et al.  The value of anti-Müllerian hormone measurement in the long GnRH agonist protocol: association with ovarian response and gonadotrophin-dose adjustments , 2012, Human reproduction.

[29]  Jiayin Liu,et al.  Comparisons of GnRH antagonist versus GnRH agonist protocol in poor ovarian responders undergoing IVF. , 2011, Human reproduction.

[30]  G. Guyatt,et al.  GRADE guidelines: 4. Rating the quality of evidence--study limitations (risk of bias). , 2011, Journal of clinical epidemiology.

[31]  I. Izhaki,et al.  Early and short follicular gonadotropin-releasing hormone antagonist supplementation improves the meiotic status and competence of retrieved oocytes in in vitro fertilization-embryo transfer cycles. , 2010, Fertility and sterility.

[32]  R. Davar,et al.  GnRH antagonist/letrozole versus microdose GnRH agonist flare protocol in poor responders undergoing in vitro fertilization. , 2010, Taiwanese journal of obstetrics & gynecology.

[33]  T. Gurgan,et al.  Comparison of microdose flare-up and antagonist multiple-dose protocols for poor-responder patients: a randomized study. , 2009, Fertility and sterility.

[34]  H. Yarali,et al.  Antagonist/letrozole protocol in poor ovarian responders for intracytoplasmic sperm injection: a comparative study with the microdose flare-up protocol. , 2009, Fertility and sterility.

[35]  C. Atabekoğlu,et al.  Microdose gonadotropin-releasing hormone agonist flare-up protocol versus multiple dose gonadotropin-releasing hormone antagonist protocol in poor responders undergoing intracytoplasmic sperm injection-embryo transfer cycle. , 2009, Fertility and sterility.

[36]  C. McCulloch,et al.  A quantitative assessment of follicle size on oocyte developmental competence. , 2008, Fertility and sterility.

[37]  E. Kolibianakis,et al.  Flexible GnRH antagonist versus flare-up GnRH agonist protocol in poor responders treated by IVF: a randomized controlled trial. , 2008, Human reproduction.

[38]  S. Özdemir,et al.  Comparison of multiple dose GnRH antagonist and minidose long agonist protocols in poor responders undergoing in vitro fertilization: a randomized controlled trial , 2008, Archives of Gynecology and Obstetrics.

[39]  A. Coomarasamy,et al.  A three-arm randomised controlled trial comparing Gonadotrophin Releasing Hormone (GnRH) agonist long regimen versus GnRH agonist short regimen versus GnRH antagonist regimen in women with a history of poor ovarian response undergoing in vitro fertilisation (IVF) treatment: Poor responders intervent , 2007, Reproductive health.

[40]  D. Peak,et al.  Novel follicular-phase gonadotropin-releasing hormone antagonist stimulation protocol for in vitro fertilization in the poor responder. , 2007, Fertility and sterility.

[41]  C. Lambalk,et al.  A systematic review of tests predicting ovarian reserve and IVF outcome. , 2006, Human reproduction update.

[42]  S. Oehninger,et al.  Controlled ovarian hyperstimulation protocols for in vitro fertilization: two decades of experience after the birth of Elizabeth Carr. , 2005, Fertility and sterility.

[43]  Hsin‐Fu Chen,et al.  Ovarian response and follicular development for single-dose and multiple-dose protocols for gonadotropin-releasing hormone antagonist administration. , 2005, Fertility and sterility.

[44]  P. Lam,et al.  GnRH antagonist versus long GnRH agonist protocol in poor responders undergoing IVF: a randomized controlled trial. , 2005, Human reproduction.

[45]  C. Matthews,et al.  The influence of body mass index, basal FSH and age on the response to gonadotrophin stimulation in non-polycystic ovarian syndrome patients. , 2002, Human reproduction.

[46]  W. Schoolcraft,et al.  Evaluating strategies for improving ovarian response of the poor responder undergoing assisted reproductive techniques. , 2000, Fertility and sterility.

[47]  E. Surrey,et al.  Clinical and endocrine effects of a microdose GnRH agonist flare regimen administered to poor responders who are undergoing in vitro fertilization. , 1998, Fertility and sterility.

[48]  E. Surrey,et al.  Short-term endocrine response to gonadotropin-releasing hormone agonist initiated in the early follicular, midluteal, or late luteal phase in normally cycling women. , 1995, Fertility and sterility.

[49]  D. Navot,et al.  Enhancement of ovarian responsiveness with microdoses of gonadotropin-releasing hormone agonist during ovulation induction for in vitro fertilization. , 1994, Fertility and sterility.

[50]  H. Judd,et al.  A prospective randomized comparison of luteal phase versus concurrent follicular phase initiation of gonadotropin-releasing hormone agonist for in vitro fertilization. , 1992, Fertility and sterility.

[51]  M. Eijkemans,et al.  Ovarian response prediction in GnRH antagonist treatment for IVF using anti-Müllerian hormone. , 2015, Human reproduction.

[52]  Julie Brown,et al.  Assisted reproductive technology: an overview of Cochrane reviews. , 2014, The Cochrane database of systematic reviews.

[53]  A. Coomarasamy,et al.  Long gonadotropin-releasing hormone agonist versus short agonist versus antagonist regimens in poor responders undergoing in vitro fertilization: a randomized controlled trial. , 2014, Fertility and sterility.

[54]  T. Dagklis,et al.  GnRH antagonist versus long GnRH agonist protocol in poor IVF responders: a randomized clinical trial. , 2013, European journal of obstetrics, gynecology, and reproductive biology.

[55]  D. Gardner,et al.  Management of poor responders: can outcomes be improved with a novel gonadotropin-releasing hormone antagonist/letrozole protocol? , 2008, Fertility and sterility.

[56]  R. Clarizia,et al.  Gonadotropin-releasing hormone (GnRH) antagonist plus recombinant luteinizing hormone vs. a standard GnRH agonist short protocol in patients at risk for poor ovarian response. , 2006, Fertility and sterility.

[57]  B. Tarlatzis,et al.  Clinical management of low ovarian response to stimulation for IVF: a systematic review. , 2003, Human reproduction update.